Literature DB >> 33849065

Risk factors for non-cancer death after surgery in patients with stage I non-small-cell lung cancer.

Ryu Kanzaki1, Akihiro Nagoya1, Takashi Kanou1, Naoko Ose1, Soichiro Funaki1, Masato Minami1, Yuna Okamoto2, Hiroto Tabuchi2, Tomoko Hoshino2, Tetsuya Tajima3, Makoto Fujii3, Yuko Ohno3, Yasushi Shintani1.   

Abstract

OBJECTIVES: With improvements in the outcome of treatment for non-small-cell lung cancer (NSCLC), other diseases may account for a high death rate after surgery in patients with stage I NSCLC. In the present study, we analysed the associations between the clinical factors and non-cancer death after surgery in these patients.
METHODS: The records of 514 patients with stage I NSCLC who underwent surgery were retrospectively reviewed; a proportional hazards model for the subdistribution of a competing risk was conducted to define the risk factors for non-cancer death.
RESULTS: The mean patient age was 67 years. A total of 367 patients (71%) underwent bilobectomy or lobectomy while 147 (29%) underwent sublobar resection. The pathological stage was IA in 386 (75%) and IB in 128 (25%) patients. Three patients (0.6%) died within 90 days after surgery, and 108 (21%) experienced postoperative complications. Until the time of writing this report, 83 patients had died during the follow-up. The cause of death was primary lung cancer in 38 (46%) patients and other diseases in 45 (54%) patients, including non-cancer causes in 29 patients, such as pneumonia, cardiac death and cerebral stroke. According to a multivariable competing risk analysis for non-cancer death age (≥70 years), sex (male), body mass index (BMI <18.5), postoperative complications and % forced expiratory volume in 1 s (<80) were identified as risk factors for postoperative non-cancer death.
CONCLUSIONS: Advanced age (≥70 years), male sex, low BMI (<18.5), postoperative complications and low preoperative % forced expiratory volume in 1 s (<80) were found to be the risk factors for postoperative non-cancer death after surgery in patients with stage I NSCLC.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Lung cancer; Non-cancer death; Pulmonary function test; Surgery

Year:  2021        PMID: 33849065     DOI: 10.1093/ejcts/ezaa333

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

1.  Clinical utility of psoas muscle volume in assessment of sarcopenia in patients with early-stage non-small cell lung cancer.

Authors:  Yuki Yamada; Yoshihisa Shimada; Yojiro Makino; Yujin Kudo; Sachio Maehara; Takafumi Yamada; Masaru Hagiwara; Masatoshi Kakihana; Tatsuo Ohira; Norihiko Ikeda
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-02       Impact factor: 4.322

2.  Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer.

Authors:  Jiaqi Li; Man Liu; Xue Zhang; Longtao Ji; Ting Yang; Yutong Zhao; Zhi Wang; Feifei Liang; Liping Dai
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-20       Impact factor: 4.322

3.  Utility of the surgical Apgar score for predicting the short- and long-term outcomes in non-small-cell lung cancer patients who undergo surgery.

Authors:  Akihiro Nagoya; Ryu Kanzaki; Kenji Kimura; Eriko Fukui; Takashi Kanou; Naoko Ose; Soichiro Funaki; Masato Minami; Makoto Fujii; Yasushi Shintani
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-07-09

4.  Preoperative Master's double two-step test may predict survival after lobectomy in patients with lung cancer.

Authors:  Satoshi Shiono; Makoto Endo; Kenta Nakahashi; Marina Nakatsuka
Journal:  J Cardiothorac Surg       Date:  2022-05-03       Impact factor: 1.522

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.